Early, appropriate antibacterial therapy is a key factor in effectively managing septic critically ill patients 1 . The prescriber must not only employ an agent of appropriate spectrum, but also in an adequate dose to achieve bacterial eradication at the site of infection. However, the relationship between drug administration and therapeutic success is complex in the critically ill, such that a patient's physiology heavily influences the way drugs distribute into tissue and are eliminated. This represents a significant challenge to the emergency or intensive care physician, and in this manner, personalising therapy, through a greater understanding of how a drug will behave in an individual patient, is likely to lead to improved outcomes.
In this edition of Anaesthesia and Intensive Care there are three articles that nicely describe some of the barriers to optimal antibacterial prescription in the critically ill. Together they contribute key information in improving our understanding of how to recognise, and treat, patients 'at-risk' of subtherapeutic drug exposure.
The first article describes some of the key fluid shifts that routinely occur in critically ill patients 2 , while the second 3 highlights that we can now measure cardiac output in a relatively easy, noninvasive fashion. This work is in keeping with that of McLean et al, recently published in this journal 4 . The third paper 5 emphasises that 'package insert' doses of vancomycin (1.0 g bd) are not enough to fill the extra fluid compartments that Sanchez et al describe. Separately, and synergistically, each paper provides important insight into optimising individual antibacterial therapy.
Sanchez et al describes the haemodynamic changes observed after fluid resuscitation for septic shock 2 . As stated by the authors, "fluid resuscitation can increase hydrostatic pressure, inducing accumulation of interstitial fluid and worsening of tissue oedema". The physiochemical properties of a molecule will determine the consequences of these effects on distribution. Antibacterials such as the β-lactams, aminoglycosides and glycopeptides "go where the water goes", meaning that in the acute resuscitation phase of critical illness, these drugs will be preferentially 'dragged' into the interstitial space by extra-vascular movement of free fluid. This in turn means that the volume of distribution (V d ) of such drugs is much higher than would be the case if there were no 'leaky' capillaries. Notably, distribution into a larger V d will result in lower serum concentrations for any given dose, or conversely a larger dose is required to compensate for the increased V d . Not unexpectedly, as patients improve, fluid redistribution from tissues into the vascular space occurs, resulting in a significant decrease in the V d , and a return to values similar to that observed in the non-critically ill 6 . As such, the time course of changes in pathophysiology mirrors that of drug pharmacokinetics. This means for drugs that distribute into extravascular interstitial fluid that 1) a loading dose is required to adequately 'fill' these compartments 7 and 2) the V d will change in parallel with the patients' physiology.
The altered V d of hydrophilic agents in the presence of sepsis helps to explain why Chung et al documented the need for higher doses of vancomycin in order to reach target serum concentrations 5 , and reinforces that use of standard 'ward' doses are likely to be inadequate in ICU patients. Such a finding is consistent with previous work in critically ill paediatric patients 6 , while an increasing index of illness severity has also been correlated with a larger V d for amikacin 8 . A larger V d is also well described for β-lactams in this setting 9 , while the importance of higher loading doses to achieve rapid therapeutic concentrations of vancomycin has been separately demonstrated 7 .
It is noteworthy that this phenomenon is in contrast to drugs that distribute into all tissues and cells of the body 10 . These moderately lipophilic antibacterials, such as the quinolones, have an inherently larger V d and therefore the relative change in V d due to the fluid shifts of acute illness has far less influence.
With newer technology available in the ICU, measurement of bedside cardiac output is safe and easily accessible 3, 4 . Similarly to fluid mediated changes in V d , the relevance of cardiac output to drug dosing has pharmacokinetic validity, and has been correlated with clearance of both hepatically 11 and renally eliminated drugs 12 . In this respect, the administration of large volumes of fluid in response to endothelial dysfunction leads to increased cardiac output, organ perfusion and delivery of solute to drug eliminating organs, primarily the liver and kidney. In terms of renal function, this phenomenon has recently been termed augmented renal clearance (ARC) 13 .
The challenge of identifying ARC is that serum creatinine concentrations are almost always within the 'normal range', while measured creatinine clearances suggest glomerular filtration is in fact significantly elevated, even as high as 200% of normal in select cases 14 . Clearly use of an isolated serum creatinine concentration to extrapolate GFR is not possible in this situation, and therefore commonly used mathematical estimates derived from noncritically ill patient populations are flawed, as they fail to account for underlying changes in physiology 15 . In this setting we have found clinical benefit in measuring cardiac output, as higher values in combination with 'normal' serum creatinine concentrations are suggestive of the presence of ARC. Similarly, a timed urinary creatinine clearance provides a simple, cheap and repeatable estimate of renal drug elimination 16 , and affords an alternate means of identifying such patients. From an anti-bacterial prescribing perspective, ARC will lead to an increased rate of drug elimination, and therefore more frequent intermittent doses, or administration by continuous or extended infusion may be required 17 , depending on the pharmacodynamics of the prescribed agent.
In conclusion, the independently submitted papers in this edition of Anaesthesia and Intensive Care 2,3,5 cumulatively describe important factors that affect antibacterial dosing requirements in the critically ill, and highlight that an improved understanding of altered physiology on pharmacokinetics is key to understanding the nuances of antibacterial prescription in this population. 
